Similarly, MGMT promoter methylation and TERT promoter mutations, both well-known molecular markers correlated to drug-resistance in gliomas, were also found to be preserved in GBM primary cells but lost in grade II/III primary cells. The gene discussed is MGMT; the disease is central nervous system cancer.